Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

ema.europa.eu

What's new

Get the latest updates from What's new directly as they happen.

Follow now 333 followers

Latest posts

Last updated 2 days ago

Human medicines European public assessment report (EPAR): Rexatilux, ranibizumab, Date of authorisation: 19/06/2026, Status: Authorised

2 days ago

Human medicines European public assessment report (EPAR): Rexatilux, ranibizumab, Date of authorisation...

EMA/PE/0000238858

2 days ago

EMA/PE/0000238858

EMA/PE/0000230610

2 days ago

EMA/PE/0000230610

EMA/PE/0000234516

2 days ago

EMA/PE/0000234516

EMA/PE/0000182225

2 days ago

EMA/PE/0000182225

EMA/PE/0000239753

2 days ago

EMA/PE/0000239753

EMA/PE/0000237903

2 days ago

EMA/PE/0000237903

Human medicines European public assessment report (EPAR): Redemplo, plozasiran, Date of authorisation: 19/06/2026, Status: Authorised

2 days ago

Human medicines European public assessment report (EPAR): Redemplo, plozasiran, Date of authorisation...

Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Date of authorisation: 11/02/2021, Revision: 21, Status: Authorised

2 days ago

Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Date of authorisation...

Human medicines European public assessment report (EPAR): Opuviz, aflibercept, Date of authorisation: 13/11/2024, Revision: 4, Status: Authorised

2 days ago

Human medicines European public assessment report (EPAR): Opuviz, aflibercept, Date of authorisation...

Human medicines European public assessment report (EPAR): Pyzchiva, ustekinumab, Date of authorisation: 19/04/2024, Revision: 15, Status: Authorised

2 days ago

Human medicines European public assessment report (EPAR): Pyzchiva, ustekinumab, Date of authorisation...

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 7, Status: Authorised

2 days ago

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation...